Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model
OBJECTIVE To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide. METHODS In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately af...
Gespeichert in:
| Veröffentlicht in: | Archives of ophthalmology (1960) 2008-07, Vol.126 (7), p.946-952 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 952 |
|---|---|
| container_issue | 7 |
| container_start_page | 946 |
| container_title | Archives of ophthalmology (1960) |
| container_volume | 126 |
| creator | Criswell, Mark H Hu, Wen-Zheng Steffens, Timothy J Li, Ruihong Margaron, Philippe |
| description | OBJECTIVE To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide. METHODS In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately after undergoing the laser procedure, animals received intravitreal injections of pegaptanib sodium, 8 or 17 μg; triamcinolone acetonide, 200 μg; or a vehicle solution. After 21 days, fluorescein angiography was performed. The CNVM mean diameters and radial thicknesses were measured histologically. RESULTS Mean CNVM diameters were 10% to 13% smaller in pegaptanib-treated eyes and 43% smaller in triamcinolone-treated eyes compared with laser-only control eyes. Late-stage fluorescein angiography leakage scores, on a scale of 0 to 3, suggested a statistical difference between triamcinolone- (0.6) and pegaptanib8 μg-treated (1.5) groups compared with the laser-only control group (2.0). The CNVM mean thicknesses were greater in the pegaptanib8 μg- (79 μm) and pegaptanib17 μg-treated (71 μm) groups and significantly smaller in the triamcinolone-treated group (26 μm) compared with the laser-only control group (67 μm). CONCLUSION In this animal model of choroidal neovascularization, intravitreal pegaptanib exhibited marginal or no effect on CNVM development; whereas intravitreal triamcinolone evoked robust inhibition of CNVMs. CLINICAL RELEVANCE Pegaptanib treatment may be insufficient to prevent CNVM formation.Arch Ophthalmol. 2008;126(7):946-952--> |
| doi_str_mv | 10.1001/archopht.126.7.946 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69321567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>420653</ama_id><sourcerecordid>69321567</sourcerecordid><originalsourceid>FETCH-LOGICAL-a486t-6dea288b71abe31f84ae964adf7c9945eba4831d28ef70ca566236a0ad33549b3</originalsourceid><addsrcrecordid>eNpdkE2LFDEQhoMo7uzoD9CDBEFvPea7k6MM6yqsH8h6lFCdTu9k6U7apFtYf72RGVfwVBT1vC_Fg9BzSnaUEPoGsjuk-bDsKFO7dmeEeoA2VHLdcEXoQ7QhhPDGGEnO0Hkpt3VVlJjH6IxqxaQRdIO-79M0Qw7xBn_xNzAvEEOHIfb4OgeYXIhpTNHji2EIDtwdDhEvB4-_woL3h5RT6GHEn3z6CcWtY236BUtIEX9MvR-foEcDjMU_Pc0t-vbu4nr_vrn6fPlh__aqAaHV0qjeA9O6ayl0ntNBC_BGCeiH1hkjpO8qx2nPtB9a4kAqxbgCAj3nUpiOb9HrY--c04_Vl8VOoTg_jhB9WotVhjMqVVvBl_-Bt2nNsf5mGadGUtWKCrEj5HIqJfvBzjlMkO8sJfaPefvXvK3mbWur-Rp6cWpeu8n3_yIn1RV4dQKqKRiHDNGFcs8xIrSm9dEtenbkYIL7q2BESc5_A__dlsE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>231951674</pqid></control><display><type>article</type><title>Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Criswell, Mark H ; Hu, Wen-Zheng ; Steffens, Timothy J ; Li, Ruihong ; Margaron, Philippe</creator><creatorcontrib>Criswell, Mark H ; Hu, Wen-Zheng ; Steffens, Timothy J ; Li, Ruihong ; Margaron, Philippe</creatorcontrib><description>OBJECTIVE To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide. METHODS In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately after undergoing the laser procedure, animals received intravitreal injections of pegaptanib sodium, 8 or 17 μg; triamcinolone acetonide, 200 μg; or a vehicle solution. After 21 days, fluorescein angiography was performed. The CNVM mean diameters and radial thicknesses were measured histologically. RESULTS Mean CNVM diameters were 10% to 13% smaller in pegaptanib-treated eyes and 43% smaller in triamcinolone-treated eyes compared with laser-only control eyes. Late-stage fluorescein angiography leakage scores, on a scale of 0 to 3, suggested a statistical difference between triamcinolone- (0.6) and pegaptanib8 μg-treated (1.5) groups compared with the laser-only control group (2.0). The CNVM mean thicknesses were greater in the pegaptanib8 μg- (79 μm) and pegaptanib17 μg-treated (71 μm) groups and significantly smaller in the triamcinolone-treated group (26 μm) compared with the laser-only control group (67 μm). CONCLUSION In this animal model of choroidal neovascularization, intravitreal pegaptanib exhibited marginal or no effect on CNVM development; whereas intravitreal triamcinolone evoked robust inhibition of CNVMs. CLINICAL RELEVANCE Pegaptanib treatment may be insufficient to prevent CNVM formation.Arch Ophthalmol. 2008;126(7):946-952--></description><identifier>ISSN: 0003-9950</identifier><identifier>ISSN: 2168-6165</identifier><identifier>EISSN: 1538-3601</identifier><identifier>EISSN: 2168-6173</identifier><identifier>DOI: 10.1001/archopht.126.7.946</identifier><identifier>PMID: 18625941</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Angiogenesis Inhibitors - therapeutic use ; Animals ; Aptamers, Nucleotide - therapeutic use ; Biological and medical sciences ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - pathology ; Disease Models, Animal ; Drug therapy ; Effectiveness studies ; Eye diseases ; Fluorescein Angiography ; Glucocorticoids - therapeutic use ; Injections ; Laser Coagulation ; Male ; Medical sciences ; Miscellaneous ; Ophthalmology ; Rats ; Rats, Inbred BN ; Rodents ; Treatment Outcome ; Triamcinolone Acetonide - therapeutic use ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vitreous Body</subject><ispartof>Archives of ophthalmology (1960), 2008-07, Vol.126 (7), p.946-952</ispartof><rights>2008 INIST-CNRS</rights><rights>Copyright American Medical Association Jul 2008</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a486t-6dea288b71abe31f84ae964adf7c9945eba4831d28ef70ca566236a0ad33549b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20488169$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18625941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Criswell, Mark H</creatorcontrib><creatorcontrib>Hu, Wen-Zheng</creatorcontrib><creatorcontrib>Steffens, Timothy J</creatorcontrib><creatorcontrib>Li, Ruihong</creatorcontrib><creatorcontrib>Margaron, Philippe</creatorcontrib><title>Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model</title><title>Archives of ophthalmology (1960)</title><addtitle>Arch Ophthalmol</addtitle><description>OBJECTIVE To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide. METHODS In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately after undergoing the laser procedure, animals received intravitreal injections of pegaptanib sodium, 8 or 17 μg; triamcinolone acetonide, 200 μg; or a vehicle solution. After 21 days, fluorescein angiography was performed. The CNVM mean diameters and radial thicknesses were measured histologically. RESULTS Mean CNVM diameters were 10% to 13% smaller in pegaptanib-treated eyes and 43% smaller in triamcinolone-treated eyes compared with laser-only control eyes. Late-stage fluorescein angiography leakage scores, on a scale of 0 to 3, suggested a statistical difference between triamcinolone- (0.6) and pegaptanib8 μg-treated (1.5) groups compared with the laser-only control group (2.0). The CNVM mean thicknesses were greater in the pegaptanib8 μg- (79 μm) and pegaptanib17 μg-treated (71 μm) groups and significantly smaller in the triamcinolone-treated group (26 μm) compared with the laser-only control group (67 μm). CONCLUSION In this animal model of choroidal neovascularization, intravitreal pegaptanib exhibited marginal or no effect on CNVM development; whereas intravitreal triamcinolone evoked robust inhibition of CNVMs. CLINICAL RELEVANCE Pegaptanib treatment may be insufficient to prevent CNVM formation.Arch Ophthalmol. 2008;126(7):946-952--></description><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>Aptamers, Nucleotide - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - pathology</subject><subject>Disease Models, Animal</subject><subject>Drug therapy</subject><subject>Effectiveness studies</subject><subject>Eye diseases</subject><subject>Fluorescein Angiography</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Injections</subject><subject>Laser Coagulation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Ophthalmology</subject><subject>Rats</subject><subject>Rats, Inbred BN</subject><subject>Rodents</subject><subject>Treatment Outcome</subject><subject>Triamcinolone Acetonide - therapeutic use</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vitreous Body</subject><issn>0003-9950</issn><issn>2168-6165</issn><issn>1538-3601</issn><issn>2168-6173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE2LFDEQhoMo7uzoD9CDBEFvPea7k6MM6yqsH8h6lFCdTu9k6U7apFtYf72RGVfwVBT1vC_Fg9BzSnaUEPoGsjuk-bDsKFO7dmeEeoA2VHLdcEXoQ7QhhPDGGEnO0Hkpt3VVlJjH6IxqxaQRdIO-79M0Qw7xBn_xNzAvEEOHIfb4OgeYXIhpTNHji2EIDtwdDhEvB4-_woL3h5RT6GHEn3z6CcWtY236BUtIEX9MvR-foEcDjMU_Pc0t-vbu4nr_vrn6fPlh__aqAaHV0qjeA9O6ayl0ntNBC_BGCeiH1hkjpO8qx2nPtB9a4kAqxbgCAj3nUpiOb9HrY--c04_Vl8VOoTg_jhB9WotVhjMqVVvBl_-Bt2nNsf5mGadGUtWKCrEj5HIqJfvBzjlMkO8sJfaPefvXvK3mbWur-Rp6cWpeu8n3_yIn1RV4dQKqKRiHDNGFcs8xIrSm9dEtenbkYIL7q2BESc5_A__dlsE</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Criswell, Mark H</creator><creator>Hu, Wen-Zheng</creator><creator>Steffens, Timothy J</creator><creator>Li, Ruihong</creator><creator>Margaron, Philippe</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20080701</creationdate><title>Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model</title><author>Criswell, Mark H ; Hu, Wen-Zheng ; Steffens, Timothy J ; Li, Ruihong ; Margaron, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a486t-6dea288b71abe31f84ae964adf7c9945eba4831d28ef70ca566236a0ad33549b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>Aptamers, Nucleotide - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - pathology</topic><topic>Disease Models, Animal</topic><topic>Drug therapy</topic><topic>Effectiveness studies</topic><topic>Eye diseases</topic><topic>Fluorescein Angiography</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Injections</topic><topic>Laser Coagulation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Ophthalmology</topic><topic>Rats</topic><topic>Rats, Inbred BN</topic><topic>Rodents</topic><topic>Treatment Outcome</topic><topic>Triamcinolone Acetonide - therapeutic use</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vitreous Body</topic><toplevel>online_resources</toplevel><creatorcontrib>Criswell, Mark H</creatorcontrib><creatorcontrib>Hu, Wen-Zheng</creatorcontrib><creatorcontrib>Steffens, Timothy J</creatorcontrib><creatorcontrib>Li, Ruihong</creatorcontrib><creatorcontrib>Margaron, Philippe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of ophthalmology (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Criswell, Mark H</au><au>Hu, Wen-Zheng</au><au>Steffens, Timothy J</au><au>Li, Ruihong</au><au>Margaron, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model</atitle><jtitle>Archives of ophthalmology (1960)</jtitle><addtitle>Arch Ophthalmol</addtitle><date>2008-07-01</date><risdate>2008</risdate><volume>126</volume><issue>7</issue><spage>946</spage><epage>952</epage><pages>946-952</pages><issn>0003-9950</issn><issn>2168-6165</issn><eissn>1538-3601</eissn><eissn>2168-6173</eissn><abstract>OBJECTIVE To evaluate the prophylactic effect of intravitreal pegaptanib sodium on choroidal neovascularization membrane (CNVM) development and compare its performance with that of triamcinolone acetonide. METHODS In drug-treated and control groups, CNVMs were induced by laser trauma. Immediately after undergoing the laser procedure, animals received intravitreal injections of pegaptanib sodium, 8 or 17 μg; triamcinolone acetonide, 200 μg; or a vehicle solution. After 21 days, fluorescein angiography was performed. The CNVM mean diameters and radial thicknesses were measured histologically. RESULTS Mean CNVM diameters were 10% to 13% smaller in pegaptanib-treated eyes and 43% smaller in triamcinolone-treated eyes compared with laser-only control eyes. Late-stage fluorescein angiography leakage scores, on a scale of 0 to 3, suggested a statistical difference between triamcinolone- (0.6) and pegaptanib8 μg-treated (1.5) groups compared with the laser-only control group (2.0). The CNVM mean thicknesses were greater in the pegaptanib8 μg- (79 μm) and pegaptanib17 μg-treated (71 μm) groups and significantly smaller in the triamcinolone-treated group (26 μm) compared with the laser-only control group (67 μm). CONCLUSION In this animal model of choroidal neovascularization, intravitreal pegaptanib exhibited marginal or no effect on CNVM development; whereas intravitreal triamcinolone evoked robust inhibition of CNVMs. CLINICAL RELEVANCE Pegaptanib treatment may be insufficient to prevent CNVM formation.Arch Ophthalmol. 2008;126(7):946-952--></abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>18625941</pmid><doi>10.1001/archopht.126.7.946</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9950 |
| ispartof | Archives of ophthalmology (1960), 2008-07, Vol.126 (7), p.946-952 |
| issn | 0003-9950 2168-6165 1538-3601 2168-6173 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69321567 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Angiogenesis Inhibitors - therapeutic use Animals Aptamers, Nucleotide - therapeutic use Biological and medical sciences Choroidal Neovascularization - drug therapy Choroidal Neovascularization - pathology Disease Models, Animal Drug therapy Effectiveness studies Eye diseases Fluorescein Angiography Glucocorticoids - therapeutic use Injections Laser Coagulation Male Medical sciences Miscellaneous Ophthalmology Rats Rats, Inbred BN Rodents Treatment Outcome Triamcinolone Acetonide - therapeutic use Vascular Endothelial Growth Factor A - antagonists & inhibitors Vitreous Body |
| title | Comparing Pegaptanib and Triamcinolone Efficacy in the Rat Choroidal Neovascularization Model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A25%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparing%20Pegaptanib%20and%20Triamcinolone%20Efficacy%20in%20the%20Rat%20Choroidal%20Neovascularization%20Model&rft.jtitle=Archives%20of%20ophthalmology%20(1960)&rft.au=Criswell,%20Mark%20H&rft.date=2008-07-01&rft.volume=126&rft.issue=7&rft.spage=946&rft.epage=952&rft.pages=946-952&rft.issn=0003-9950&rft.eissn=1538-3601&rft_id=info:doi/10.1001/archopht.126.7.946&rft_dat=%3Cproquest_cross%3E69321567%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=231951674&rft_id=info:pmid/18625941&rft_ama_id=420653&rfr_iscdi=true |